Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside
Yıl: 2019 Cilt: 28 Sayı: 2 Sayfa Aralığı: 138 - 146 Metin Dili: İngilizce DOI: 10.5152/turkjnephrol.2019.3504 İndeks Tarihi: 21-07-2020
Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside
Öz: Anemia is one of the common chronic renal failure (CRF) complications. Reduced renal erythropoietin (EPO) productionand a shortened life span of erythrocytes due to uremic environment and iron deficiency are the main causes of anemia inpatients with CRF. Correcting of iron deficiency constitutes the basis for the treatment of anemia in patients with CRF. Ironreplacement can be done orally or intravenously. The seriousness of anemia and iron deficiency, tolerance of tablet use, response to previous treatments, and the presence of a ready vascular access determine the manner in which iron treatmentis done. New generation parenteral iron preparations have complex carbohydrate structures that strongly bind to iron andreduce plasma free iron release. New generation iron molecules correct iron deficiency without causing an inflammatoryprocess. The point that should be kept in mind is that new formulations may have a side effect profile that has not yet beenexperienced, in addition to various advantages. When using new iron molecules, precaution measures should be takenwith regard to the development of arrhythmia, unstable angina, and hypophosphatemia.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-8. [CrossRef]
- 2. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, et al. Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38: 803-12. [CrossRef]
- 3. Seyahi N, Ateş K, Süleymanlar G. Current Status of Renal Replacement Therapies in Turkey: Summary of Turkish Society of Nephrology Registry 216 Report. Turk Neph Dial Transpl; 2018; 27: 133-9.
- 4. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int 2005; 67: 1483-8. [CrossRef]
- 5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335.
- 6. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-73.
- 7. Astor BC, Arnett DK, Brown A, Coresh J. Association of Kidney Function and Hemoglobin with Left Ventricular Morphology among African Americans: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2004; 43: 836-45. [CrossRef]
- 8. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13: 1928-36. [CrossRef]
- 9. Chang JM, Chen SC, Huang JC, Su HM, Chen HC. Anemia and Left Ventricular Hypertrophy With Renal Function Decline and Cardiovascular Events in Chronic Kidney Disease. Am J Med Sci 2014; 347: 183-9. [CrossRef]
- 10. Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W. Hemoglobin Targets for Chronic Kidney Disease Patients with Anemia: A Systematic Review and Meta-analysis. PLoS One 2012; 7: e43655. [CrossRef]
- 11. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-32. [CrossRef]
- 12. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): Current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005; 20 Suppl 3: iii3-24. [CrossRef]
- 13. Valderrábano F, Hörl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18: 89-100. [CrossRef]
- 14. Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am J Kidney Dis 2018; 71: 423-35. [CrossRef]
- 15. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013; 161: 639-48. [CrossRef]
- 16. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346-59. [CrossRef]
- 17. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients: The Role of Inflammation. Clin J Am Soc Nephrol 2008; 3: 1691-701. [CrossRef]
- 18. Stinghen AE, Gonçalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract 2009; 111: c117-26. [CrossRef]
- 19. Zimmermann J, Herrlinger S, Pruy a, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58. [CrossRef]
- 20. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: ımplications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726- 41. [CrossRef]
- 21. Babitt JL, Lin HY. Scinence ın renal medicine mechanisms of anemia in CKD. J Am Soc Nephrol 2012; 23: 1631-4. [CrossRef]
- 22. E. Nemeth. Hepcidin regulates cellular ıron efflux by binding to ferroportin and ınducing ıts ınternalization. Science 2004; 306: 2090- 3. [CrossRef]
- 23. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346-59. [CrossRef]
- 24. National Institute for Health and Clinical Excellence. Chronic kidney disease in adults: assessment and management. NICE Guidel. 2014.
- 25. Singh AK, Coyne DW, Shapiro W, Rizkala AR, the DRIVE Study Group. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-71. [CrossRef]
- 26. Kalantar-Zadeh K. Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients. J Am Soc Nephrol 2005; 16: 3070-80. [CrossRef]
- 27. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41-6. [CrossRef]
- 28. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review and Meta-analysis. Am J Kidney Dis 2008; 52: 897-906. [CrossRef]
- 29. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-89. [CrossRef]
- 30. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 2010; 26: 473-82. [CrossRef]
- 31. Fishbane S, Kowalski E a, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7: 2654-7.
- 32. Stancu S, Bârsan L, Stanciu A, Mircescu GM. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol 2010; 5: 409-16. [CrossRef]
- 33. Heath CW, Strauss MB CW. Quantitative aspects of iron deficiency in hypochromic anemia. J Clin Invest 1932; 11: 1293-312. [CrossRef]
- 34. Nissim J. Intravenous administration of iron. Lancet 1947; 1: 49-51. [CrossRef]
- 35. Macdougall LC. Evolution of IV iron compounds over the last century. J Ren Care 2009; 35: 8-13. [CrossRef]
- 36. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung 2010; 60: 345-53.
- 37. Saglam F, Cavdar C, Uysal S, Cavdar Z, Camsari T. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients. Ren Fail 2007; 29: 849-54. [CrossRef]
- 38. Jairam A, Das R, Aggarwal PK, Kohli HS, Gupta KL, Sakhuja V, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J Nephrol 2010; 20: 125-31. [CrossRef]
- 39. Cavdar C, Temiz A, Yeniçerioğlu Y, Calişkan S, Celik A, Sifil A, et al. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol 2003; 37: 77-82. [CrossRef]
- 40. Agarwal R, Leehey DJ, Olsen SM, Dahl N V. Proteinuria induced by parenteral iron in chronic kidney disease - A comparative randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 114-21. [CrossRef]
- 41. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905-14. [CrossRef]
- 42. Merkofer M, Kissner R, Hider RC, Brunk UT, Koppenol WH. Fenton chemistry and iron chelation under physiologically relevant conditions: Electrochemistry and kinetics. Chem Res Toxicol 2006; 19: 1263-9. [CrossRef]
- 43. Pai AB, Conner T, McQuade CR, Olp J, Hicks P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011; 24: 603-13. [CrossRef]
- 44. Zager RA, Johnson ACM, Hanson SY, Wasse H. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103. [CrossRef]
- 45. Pai AB, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007; 27: 343-50. [CrossRef]
- 46. Van Wyck DB, Anderson J, Johnson K. Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 2004; 19: 561-5. [CrossRef]
- 47. Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 2010; 25: 3631-40. [CrossRef]
- 48. Beshara S, Sörensen J, Lubberink M, Tolmachev V, Långström B, Antoni G, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003; 120: 853-9. [CrossRef]
- 49. Prats M, Font R, García-Ruiz C, Cabré C, Mu-oz-Cortés M, Nogués MR, et al. Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure. Nefrologia 2013; 33: 355-61.
- 50. Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014; 29: 843-50. [CrossRef]
- 51. Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial. Nephrol Dial Transplant 2014; 29: 833-842. [CrossRef]
- 52. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-607. [CrossRef]
- 53. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial. Transfusion 2009; 49: 2719-28. [CrossRef]
- 54. Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol 2015; 2015: 468675. [CrossRef]
- 55. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci 2011; 108: E1146-55. [CrossRef]
- 56. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28: 1793-803. [CrossRef]
| APA | OKTAN M, Heybeli C, Cavdar Z (2019). Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. , 138 - 146. 10.5152/turkjnephrol.2019.3504 |
| Chicago | OKTAN Mehmet Ası,Heybeli Cihan,Cavdar Zahide Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. (2019): 138 - 146. 10.5152/turkjnephrol.2019.3504 |
| MLA | OKTAN Mehmet Ası,Heybeli Cihan,Cavdar Zahide Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. , 2019, ss.138 - 146. 10.5152/turkjnephrol.2019.3504 |
| AMA | OKTAN M,Heybeli C,Cavdar Z Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. . 2019; 138 - 146. 10.5152/turkjnephrol.2019.3504 |
| Vancouver | OKTAN M,Heybeli C,Cavdar Z Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. . 2019; 138 - 146. 10.5152/turkjnephrol.2019.3504 |
| IEEE | OKTAN M,Heybeli C,Cavdar Z "Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside." , ss.138 - 146, 2019. 10.5152/turkjnephrol.2019.3504 |
| ISNAD | OKTAN, Mehmet Ası vd. "Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside". (2019), 138-146. https://doi.org/10.5152/turkjnephrol.2019.3504 |
| APA | OKTAN M, Heybeli C, Cavdar Z (2019). Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. Turkish journal of nephrology (Online), 28(2), 138 - 146. 10.5152/turkjnephrol.2019.3504 |
| Chicago | OKTAN Mehmet Ası,Heybeli Cihan,Cavdar Zahide Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. Turkish journal of nephrology (Online) 28, no.2 (2019): 138 - 146. 10.5152/turkjnephrol.2019.3504 |
| MLA | OKTAN Mehmet Ası,Heybeli Cihan,Cavdar Zahide Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. Turkish journal of nephrology (Online), vol.28, no.2, 2019, ss.138 - 146. 10.5152/turkjnephrol.2019.3504 |
| AMA | OKTAN M,Heybeli C,Cavdar Z Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. Turkish journal of nephrology (Online). 2019; 28(2): 138 - 146. 10.5152/turkjnephrol.2019.3504 |
| Vancouver | OKTAN M,Heybeli C,Cavdar Z Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside. Turkish journal of nephrology (Online). 2019; 28(2): 138 - 146. 10.5152/turkjnephrol.2019.3504 |
| IEEE | OKTAN M,Heybeli C,Cavdar Z "Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside." Turkish journal of nephrology (Online), 28, ss.138 - 146, 2019. 10.5152/turkjnephrol.2019.3504 |
| ISNAD | OKTAN, Mehmet Ası vd. "Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside". Turkish journal of nephrology (Online) 28/2 (2019), 138-146. https://doi.org/10.5152/turkjnephrol.2019.3504 |
